Kestra Investment Management LLC Takes Position in United Therapeutics Co. (NASDAQ:UTHR)

Kestra Investment Management LLC purchased a new stake in shares of United Therapeutics Co. (NASDAQ:UTHR - Free Report) in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The fund purchased 1,708 shares of the biotechnology company's stock, valued at approximately $603,000.

Several other institutional investors have also made changes to their positions in the company. Wealth Enhancement Advisory Services LLC lifted its holdings in United Therapeutics by 0.8% in the 4th quarter. Wealth Enhancement Advisory Services LLC now owns 4,913 shares of the biotechnology company's stock worth $1,761,000 after purchasing an additional 39 shares during the last quarter. MBM Wealth Consultants LLC lifted its holdings in United Therapeutics by 1.9% in the 4th quarter. MBM Wealth Consultants LLC now owns 2,151 shares of the biotechnology company's stock worth $775,000 after purchasing an additional 41 shares during the last quarter. Signaturefd LLC lifted its holdings in United Therapeutics by 8.8% in the 3rd quarter. Signaturefd LLC now owns 633 shares of the biotechnology company's stock worth $227,000 after purchasing an additional 51 shares during the last quarter. UMB Bank n.a. lifted its holdings in United Therapeutics by 4.9% in the 4th quarter. UMB Bank n.a. now owns 1,101 shares of the biotechnology company's stock worth $388,000 after purchasing an additional 51 shares during the last quarter. Finally, MassMutual Private Wealth & Trust FSB lifted its holdings in United Therapeutics by 31.9% in the 4th quarter. MassMutual Private Wealth & Trust FSB now owns 240 shares of the biotechnology company's stock worth $85,000 after purchasing an additional 58 shares during the last quarter. 94.08% of the stock is currently owned by institutional investors and hedge funds.

United Therapeutics Price Performance

Shares of UTHR traded down $6.26 on Friday, reaching $361.10. 407,154 shares of the stock traded hands, compared to its average volume of 347,037. The firm has a market cap of $16.12 billion, a price-to-earnings ratio of 15.86, a P/E/G ratio of 0.99 and a beta of 0.57. United Therapeutics Co. has a 12 month low of $214.75 and a 12 month high of $417.82. The stock's 50-day moving average price is $362.70 and its 200-day moving average price is $359.94.

Analyst Ratings Changes

Several equities research analysts recently weighed in on the company. StockNews.com upgraded United Therapeutics from a "buy" rating to a "strong-buy" rating in a report on Thursday, January 16th. UBS Group lifted their price target on United Therapeutics from $415.00 to $475.00 and gave the stock a "buy" rating in a research report on Wednesday, January 8th. Oppenheimer lifted their price target on United Therapeutics from $575.00 to $600.00 and gave the stock an "outperform" rating in a research report on Thursday, October 31st. HC Wainwright lifted their price target on United Therapeutics from $400.00 to $425.00 and gave the stock a "buy" rating in a research report on Thursday, October 31st. Finally, The Goldman Sachs Group lifted their price target on United Therapeutics from $243.00 to $302.00 and gave the stock a "neutral" rating in a research report on Friday, November 1st. One analyst has rated the stock with a sell rating, two have given a hold rating, ten have assigned a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, United Therapeutics currently has a consensus rating of "Moderate Buy" and an average target price of $382.08.

Insider Activity at United Therapeutics

In related news, COO Michael Benkowitz sold 10,000 shares of the business's stock in a transaction on Monday, February 10th. The stock was sold at an average price of $348.06, for a total value of $3,480,600.00. Following the sale, the chief operating officer now owns 2,577 shares of the company's stock, valued at $896,950.62. The trade was a 79.51 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Louis W. Sullivan sold 26,209 shares of the business's stock in a transaction on Wednesday, December 18th. The stock was sold at an average price of $373.22, for a total value of $9,781,722.98. Following the completion of the transaction, the director now directly owns 5,051 shares in the company, valued at approximately $1,885,134.22. This represents a 83.84 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 124,164 shares of company stock valued at $45,398,793 in the last 90 days. 11.90% of the stock is owned by corporate insiders.

United Therapeutics Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.